Interestingly, GLP-1 receptor agonists have shown beneficial effects on cardiovascular health. Several clinical trials have demonstrated that these drugs can reduce the risk of major cardiovascular events, making them an attractive option for patients with type 2 diabetes and cardiovascular disease. However, in toxicological terms, continuous evaluation is necessary to ensure that long-term use does not introduce unforeseen cardiovascular risks.
